English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Apoptosis inhibition in chronic lymphocytic leukemia (CLL) is one of the most important mechanism in the disease onset, progression and therapy response and is dependent of interaction with different microenvironments. Aim of our paper is to determine expression of antiapoptoic proteins mcl-1 and bcl-2 in CLL cells isolated from two different compartments (peripheral blood and bone marrow) and its relation to percent of apoptotic cells and concentration of growth factors (FGF and VEGF). Our results showed that peripheral blood CLL lymphocytes have lower apoptotic rate then those isolated from bone marrow, though bone marrow CLL lymphocytes express higher levels of antipoptotic proteins bcl-2 and mcl-1. In bone marrow FGF concentration is 10-fold higher then in patients plasma but has an limited impact on mcl-1 expression. In contrary, VEGF concentration is higher in peripheral blood and corelate with percent of apoptotic cells and mcl-1 expression in this compartment. CLL cells derived from two different microenvironmets acts differently when tested for apoptosis „ex vivo“. In peripheral blood apoptosis is strongly connected with expression of antiapoptoic proteins (mcl-1 and bcl-2) and growth factors, but not in bone marrow.

serbian journal of experimental and clinical research

Antiapoptotic Proteins mcl-1 and bcl-2 as well as Growth Factors FGF and VEGF Influence Survival of Peripheral Blood and Bone Marrow Chronic Lymphocytic Leukemia Cells